Skip to content

Discontinued — last reported Q1 '25

Interest Expense at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.9M+48.3%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$14.96M+422%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$49.03M-43.8%
Insmed logo
InsmedINSM
$20.08M-6.9%
uniQure logo
uniQureQURE
$14.03M-7.1%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$7.75M+5.6%

Segments

By segment

See full
All Other Segments$21.71M+382%

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestExpense.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s interest expense?
Sarepta Therapeutics, Inc. (SRPT) reported interest expense of -$4.5M in Q1 2025.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.